NAT Testing Management Equipment Service

NHSBT is a Special Health Authority, responsible for the provision of blood components and tissues and a range of associated specialist laboratory and patient therapeutic services. The authority’s testing function performs Nucleic Acid Amplification Technology (NAT) Testing which is the screening of blood, tissue and stem cell donations for detection of hepatitis C (HCV) ribonucleic acid (RNA), human immunodeficiency virus (HIV) RNA, hepatitis B (HBV) deoxyribonucleic acid (DNA) and west nile virus (WNV) RNA using automation systems. This VEAT is for a direct award to the current NAT provider due to the Covid-19 and NHSBT's ongoing response to the pandemic. The project team and operational teams manufacturing development team (MDT), testing and IT) have all been required to work on high priority Covid-19 activities. There are no alternative providers of technical input into any tender. This award is for a 12-month contract (October 2020-October 2021) using Regulation 32 (2) (c).
CPV-Code: 71900000
Abgabefrist:
Typ: Voluntary ex ante transparency notice
Status: Not applicable
Aufgabe: Health
Vergabestelle:
name: NHS Blood and Transplant
address: North Bristol Park, Bristol
postal_code: BS34 7QH
city: Filton - UK
country: UK
email: None
phone: +44 1179217230
contact_point:
idate: 27. November 2020 10:49
udate: 27. November 2020 10:49
doc: 574073_2020.xml
authority_types:
activities:
Quelle: http://ted.europa.eu/udl?uri=TED:NOTICE:574073-2020:TEXT:EN:HTML
Unterlagen: None
Zuschlagskriterium: Not specified
Vertrag: Services
Prozedur: Negotiated without a prior call for competition
Nuts: None
Veröffentlichung: 27.11.2020
Erfüllungsort: Filton -
Link:
Lose:
Name Los Nr 1 None
Gewinner Roche Diagnostics Ltd
Datum
Wert GB£2 500 000,00
Anzahl Angebote 1